Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Excerpt

With great deal of interest we read the article entitled “Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei (PMP) of appendiceal origin: result of a single centre study.” by Di Leo et al. [1] In the study, 32 patients were included during the period 2008–2016. Two thirds of them underwent first look surgery. In the cohort, the median operative time was 540 min and the median PCI index was 17. Complete cytoreduction (CC-0) was achieved in 69% of patients, and CC-1 in another 23%. Based on Clavien–Dindo classification, 3/32 patients had grade III complications (one with a porta-cath infection and two with pleural efusion), 1/32 had a grade IV complication (cerebral hematoma) and no grade V complications were identified. The median hospital stay was 9.5 days. In the cohort, one-year overall survival (OS) was 90% and 5-year OS was 58%. Disease-free survival (DFS), regardless of histological type, was 95% at 1 year and 46% at 5 years. A strong correlation was identified between higher initial PCI index, and 5-year OS. …